Associations of cord blood fatty acids with lymphocyte proliferation, IL-13, and IFN-γ - 17/08/11
Boston, Mass
Abstract |
Background |
N-3 and n-6 polyunsaturated fatty acids (PUFAs) have been hypothesized to have opposing influences on neonatal immune responses that might influence the risk of allergy or asthma. However, both n-3 eicosapentaenoic acid (EPA) and n-6 arachidonic acid (AA) are required for normal fetal development.
Objective |
We evaluated whether cord blood fatty acid levels were related to neonatal immune responses and whether n-3 and n-6 PUFA responses differed.
Methods |
We examined the relation of cord blood plasma n-3 and n-6 PUFAs (n = 192) to antigen- and mitogen-stimulated cord blood lymphocyte proliferation (n = 191) and cytokine (IL-13 and IFN-γ; n = 167) secretion in a US birth cohort.
Results |
Higher levels of n-6 linoleic acid were correlated with higher IL-13 levels in response to Bla g 2 (cockroach, P = .009) and Der f 1 (dust mite, P = .02). Higher n-3 EPA and n-6 AA levels were each correlated with reduced lymphocyte proliferation and IFN-γ levels in response to Bla g 2 and Der f 1 stimulation. Controlling for potential confounders, EPA and AA had similar independent effects on reduced allergen-stimulated IFN-γ levels. If neonates had either EPA or AA levels in the highest quartile, their Der f 1 IFN-γ levels were 90% lower (P = .0001) than those with both EPA and AA levels in the lowest 3 quartiles. Reduced AA/EPA ratio was associated with reduced allergen-stimulated IFN-γ level.
Conclusion |
Increased levels of fetal n-3 EPA and n-6 AA might have similar effects on attenuation of cord blood lymphocyte proliferation and IFN-γ secretion.
Clinical implications |
The implications of these findings for allergy or asthma development are not yet known.
Le texte complet de cet article est disponible en PDF.Key words : Asthma, child, cord blood, cytokine, fatty acids, lymphocyte proliferation
Abbreviations used : AA, BMI, CBMC, CI, DHA, EPA, FA, LA, NICU, OVA, PG, PUFA, SI
Plan
Supported by National Institutes of Health grants R01 HL61907, HD34568, HL64925, HL68041, and AI/EHS35786. Disclosure of potential conflict of interest: M. Gillman has received grant support from Mead Johnson Nutritionals. No Conflict of Interest disclosure statement was received from C. Schroeter. The rest of the authors have declared they have no conflict of interest. |
Vol 117 - N° 4
P. 931-938 - avril 2006 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?